Skip to main content
. 2024 May 29;44(5):BSR20230667. doi: 10.1042/BSR20230667

Figure 1. Diameter, morphology, and integrity of GBM spheroids after TMZ treatment.

Figure 1

Diameter (µm) of U251MG WTE (A) and TLS Polκ KO (B) 3D tumor spheroids treated with TMZ and respective controls at Day 0, Day 5, and Day 10. Morphology and Integrity of U251MG WTE (C) and TLS Polκ KO (D) spheroids treated with TMZ and respective controls at Day 0 and Day 10. All images were obtained using the EVOS XL microscope, using the 10x objective. All data were represented as means ± standard deviation (X ± SD) from six spheroids (n=6) per replicate and three independent biological experiments (n=3). *Values statistically different from the NC group at the point (date) (*P<0.05, **P<0.01, ***P<0.001; ANOVA followed by Dunnett’s post-test). NC: Negative Control (DMEM HG); PC: Positive Control (Cisplatin 100 μM); SC: Solvent Control (1% DMSO); TMZ: Temozolomide. Scale: 200 μm.